John R Hughes1, Matthew J Carpenter, Shelly Naud. 1. Department of Psychiatry, University of Vermont, University Health Center, Mailstop 482, 1 South Prospect Street, Burlington, VT 05401, USA. john.hughes@uvm.edu
Abstract
INTRODUCTION: Many smoking cessation trials report either prolonged abstinence (PA) rates (i.e., not smoking since a quit date, with or without a grace period) or point prevalence (PP) abstinence rates (i.e., no smoking one or more days prior to the follow-up), but how these two relate is unclear. METHODS: We located 28 pharmacotherapy trials that provided 76 within-study comparisons of PA versus PP. The first two authors independently coded all trials. RESULTS: The two measures were highly correlated (r = .88) and PA averaged 0.74 that of PP. Equations for converting PP to PA and vice versa produced estimations that, in 90% of cases, were within 4%-5% of actual PP or PA values. The odds ratio and the relative risk for active versus control were identical when PA and PP were used; however, the difference in proportion abstinent for active versus control was somewhat less when PA was used than when PP was used (8% vs. 10%). DISCUSSION: We conclude that PA and PP are closely related and can be interconverted with moderate accuracy. They also produce similar effect sizes when odds ratio and relative risk are used as effect sizes. When absolute difference in percent abstinent is used as an effect size, PA produces a smaller effect size than PP. We believe trials should continue to report both PA and PP outcomes to enhance comparisons across studies.
INTRODUCTION: Many smoking cessation trials report either prolonged abstinence (PA) rates (i.e., not smoking since a quit date, with or without a grace period) or point prevalence (PP) abstinence rates (i.e., no smoking one or more days prior to the follow-up), but how these two relate is unclear. METHODS: We located 28 pharmacotherapy trials that provided 76 within-study comparisons of PA versus PP. The first two authors independently coded all trials. RESULTS: The two measures were highly correlated (r = .88) and PA averaged 0.74 that of PP. Equations for converting PP to PA and vice versa produced estimations that, in 90% of cases, were within 4%-5% of actual PP or PA values. The odds ratio and the relative risk for active versus control were identical when PA and PP were used; however, the difference in proportion abstinent for active versus control was somewhat less when PA was used than when PP was used (8% vs. 10%). DISCUSSION: We conclude that PA and PP are closely related and can be interconverted with moderate accuracy. They also produce similar effect sizes when odds ratio and relative risk are used as effect sizes. When absolute difference in percent abstinent is used as an effect size, PA produces a smaller effect size than PP. We believe trials should continue to report both PA and PP outcomes to enhance comparisons across studies.
Authors: Robin Mermelstein; Suzanne M Colby; Christi Patten; Alexander Prokhorov; Richard Brown; Mark Myers; William Adelman; Karen Hudmon; Paul McDonald Journal: Nicotine Tob Res Date: 2002-11 Impact factor: 4.244
Authors: Saul Shiffman; Deborah M Scharf; William G Shadel; Chad J Gwaltney; Qianyu Dang; Stephanie M Paton; Duncan B Clark Journal: J Consult Clin Psychol Date: 2006-04
Authors: Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: John R Hughes; Josue P Keely; Ray S Niaura; Deborah J Ossip-Klein; Robyn L Richmond; Gary E Swan Journal: Nicotine Tob Res Date: 2003-02 Impact factor: 4.244
Authors: Danielle E McCarthy; Thomas M Piasecki; Daniel L Lawrence; Douglas E Jorenby; Saul Shiffman; Michael C Fiore; Timothy B Baker Journal: Nicotine Tob Res Date: 2008-04 Impact factor: 4.244
Authors: P L Pirie; C M McBride; W Hellerstedt; R W Jeffery; D Hatsukami; S Allen; H Lando Journal: Am J Public Health Date: 1992-09 Impact factor: 9.308
Authors: Lorra Garey; Kara Manning; Danielle E McCarthy; Matthew W Gallagher; Justin M Shepherd; Michael F Orr; Norman B Schmidt; Blaz Rodic; Michael J Zvolensky Journal: Addict Behav Date: 2019-02-21 Impact factor: 3.913
Authors: Smita Pakhale; Justine Baron; Michael A Armstrong; Avanti Garde; Robert D Reid; Gonzalo Alvarez; Debbie Aitken; Kerri-Anne Mullen; George Wells; Andrew Pipe Journal: Can Respir J Date: 2015-02-03 Impact factor: 2.409
Authors: Fenneke M van Hasselt; Paul F M Krabbe; Maarten J Postma; Anton J M Loonen Journal: Int J Methods Psychiatr Res Date: 2014-12-09 Impact factor: 4.035
Authors: Gina R Kruse; David R Bangsberg; Judith A Hahn; Jessica E Haberer; Peter W Hunt; Conrad Muzoora; John P Bennett; Jeffrey N Martin; Nancy A Rigotti Journal: AIDS Behav Date: 2014-07
Authors: Jeffery C Huffman; Ariana M Albanese; Kirsti A Campbell; Christopher M Celano; Rachel A Millstein; Carol A Mastromauro; Brian C Healy; Wei-Jean Chung; James L Januzzi; Linda M Collins; Elyse R Park Journal: Clin Trials Date: 2017-01-12 Impact factor: 2.486
Authors: Kathleen M Carroll; Brian D Kiluk; Charla Nich; Elise E DeVito; Suzanne Decker; Donna LaPaglia; Dianne Duffey; Theresa A Babuscio; Samuel A Ball Journal: Drug Alcohol Depend Date: 2014-01-31 Impact factor: 4.492
Authors: Francisco I Salgado García; Karen J Derefinko; Zoran Bursac; Sarah Hand; Robert C Klesges Journal: Contemp Clin Trials Date: 2018-03-13 Impact factor: 2.226
Authors: Deepa R Camenga; Grace Kong; Kara Bagot; Rani A Hoff; Marc N Potenza; Suchitra Krishnan-Sarin Journal: Subst Abus Date: 2014 Impact factor: 3.716